Exelixis $EXEL

Health Care · NASDAQ

$64.63
-1.20 (-1.82%)
As of Nov 20, 2026, 4:05 PM EST · cached
Price history
Loading chart…
Today's analyst average Analyst average over timeIndividual analyst targets Analyst history starts Oct 19, 2026, the first target we tracked for EXEL.

Exelixis (EXEL) is trading down at $64.63 (-1.82%) on NASDAQ, as of the latest quote. It is a Russell 1000 constituent in the Health Care sector.

Analyst price targets on EXEL

One firm's current price target on Exelixis: $65 — 1% above the current $64.6. Each is tracked to its date and scored the same way a member's call is.

1 target, newest first. Open a row for its source and scoring.

DateOct 19, 2026 FirmCitizens JMP RatingMarket Outperform · raises Targetat $62.7 · $65 +4% Horizonby Oct 2027 StatusOpen

Entry price $62.7, the close nearest Oct 19, 2026, when the target was reported; the target is +4% from it.

Horizon No horizon stated, so it is tracked over the 12-month default, to Oct 2027.

Scoring Open: judged on the close on Oct 19, 2027.

Source Citizens raises Exelixis stock price target to $65 on ESMO data Investing.com · Oct 19, 2026 · opens the publisher's site
Citizens raised its price target on Exelixis Inc. shares (NASDAQ:EXEL) to $65.00 from $55.00

Targets published by research firms, extracted from the news, checked against independent reporting, and linked to their source. Where a firm did not state a horizon the target is tracked as 12 months, the industry convention; the rows where the firm set its own horizon are marked. “At” is the closing price nearest the day the target was reported, the price we score it from; it is not an earlier target. Reported here as facts about what was published — not recommendations from Dalsna Finance, and no firm listed is affiliated with this site.

Exelixis revenue & net income history (FY2016–FY2025)

RevenueNet incomeNet margin (right axis, %)
$2.32B$1.12B−$70.2MFY2016 revenue: $191.5MFY2016 net income: −$70.2M · Net margin −36.7%'16FY2017 revenue: $452.5MFY2017 net income: $154.2M · Net margin 34.1%'17FY2018 revenue: $853.8MFY2018 net income: $690.1M · Net margin 80.8%'18FY2019 revenue: $967.8MFY2019 net income: $321.0M · Net margin 33.2%'19FY2020 revenue: $987.5MFY2020 net income: $111.8M · Net margin 11.3%'20FY2021 revenue: $1.43BFY2021 net income: $231.1M · Net margin 16.1%'21FY2022 revenue: $1.61BFY2022 net income: $182.3M · Net margin 11.3%'22FY2023 revenue: $1.83BFY2023 net income: $207.8M · Net margin 11.4%'23FY2024 revenue: $2.17BFY2024 net income: $521.3M · Net margin 24.0%'24FY2025 revenue: $2.32BFY2025 net income: $782.6M · Net margin 33.7%'250%50%100%150%200%FY2016 net margin: −36.7% (off the scale, which stops at −6.1%)FY2017 net margin: 34.1%FY2018 net margin: 80.8%FY2019 net margin: 33.2%FY2020 net margin: 11.3%FY2021 net margin: 16.1%FY2022 net margin: 11.3%FY2023 net margin: 11.4%FY2024 net margin: 24.0%FY2025 net margin: 33.7%
Exelixis annual financial statements
FY2016Dec 2016FY2017Dec 2017FY2018Dec 2018FY2019Jan 2020FY2020Jan 2021FY2021Dec 2021FY2022Dec 2022FY2023Dec 2023FY2024Jan 2025FY2025Jan 2026
Income statement
Revenue$191.5M$452.5M$853.8M$967.8M$987.5M$1.43B$1.61B$1.83B$2.17B$2.32B
Growth (year over year)+415.0%+136.3%+88.7%+13.3%+2.0%+45.3%+12.3%+13.6%+18.5%+7.0%
Gross profit$184.9M$437.4M$827.5M$934.7M$951.3M$1.38B$1.55B$1.76B$2.09B$2.24B
Gross margin96.6%96.7%96.9%96.6%96.3%96.3%96.4%96.0%96.5%96.4%
Operating income−$28.1M$165.9M$438.9M$369.5M$110.1M$286.7M$201.5M$170.9M$604.6M$872.2M
Operating margin−14.7%36.7%51.4%38.2%11.1%20.0%12.5%9.3%27.9%37.6%
Net income−$70.2M$154.2M$690.1M$321.0M$111.8M$231.1M$182.3M$207.8M$521.3M$782.6M
Net margin−36.7%34.1%80.8%33.2%11.3%16.1%11.3%11.4%24.0%33.7%
EPS (diluted)−$0.28$0.49$2.21$1.02$0.35$0.72$0.56$0.65$1.76$2.78
Balance sheet
Cash and equivalents$151.7M$183.2M$314.8M$266.5M$319.2M$647.2M$501.2M$263.0M$217.4M$482.5M
Total assets$595.7M$655.3M$1.42B$1.89B$2.14B$2.62B$3.07B$2.94B$2.95B$2.84B
Total liabilities$506.4M$370.3M$134.8M$199.7M$258.2M$405.6M$583.1M$678.4M$703.5M$683.1M
Long-term debt$0$0————————
Shareholders' equity$89.3M$285.0M$1.29B$1.69B$1.88B$2.21B$2.49B$2.26B$2.24B$2.16B
Cash flow
Operating cash flow$210.4M$165.6M$415.7M$527.0M$209.0M$400.8M$362.6M$333.3M$700.0M$884.3M
Capital expenditure$1.70M$21.1M$33.3M$12.8M$30.3M$54.2M$27.7M$40.5M$28.4M$8.43M
Free cash flow$208.7M$144.5M$382.4M$514.1M$178.6M$346.6M$334.9M$292.9M$671.5M$875.8M
Share buybacks—————$0$0$550.4M$652.0M$947.5M

From Exelixis's 10-K and 10-Q filings with the SEC; its fiscal year ends in January. Each period shows the latest figure the company has reported for it, including restatements. Net margin is our own calculation from those reported figures (net income ÷ revenue); it is left blank where revenue is zero or missing. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →

Exelixis in the news

Nov 19, 2026 Seeking Alpha Exelixis: Management’s $5 Billion Aspiration Is Already In The Share Price (NASDAQ:EXEL)
Nov 19, 2026 GlobeNewswire EXEL Industries: EXEL Industries presents a proposed transformation plan to prepare its Agricultural Spraying business for the future
Nov 18, 2026 Investing.com Exelixis at Jefferies Global Healthcare Conference: zanza buildout in focus
Nov 11, 2026 Investing.com Exelixis at Stifel 2026 Healthcare Conference: zanzalintinib push
Nov 10, 2026 Investing.com Exelixis at guggenheim healthcare innovation conference: zanza push
Show 1 older story
Oct 19, 2026 Investing.com Citizens raises Exelixis stock price target to $65 on ESMO data Target

About Exelixis

Exelixis, Inc. is a genomics-based drug discovery company located in Alameda, California, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration (FDA) for medullary thyroid cancer with clinical activity in several other types of metastatic cancer.

Source: Wikipedia — Exelixis

Headquarters
Alameda, California From SEC filings, Oct 2026

More Health Care stocks

Browse all companies →